IL1B and neoplasm: Our data indicated that treatment with quadrigemine I significantly reduced the secretion of key pro-inflammatory cytokines, such as TNF-α, IL-6, and IL-1β, in various tissues, including serum, liver, spleen, and tumor tissues (Figure 7).